ABSI

$9.46-$0.04 (-0.42%)live

Compare

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institutions

Market cap

$1.6B

172M shares

52-week range

$2.24 – $12.06

74% from low

Sector

SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH

Exchange

NASDAQ

Change$-11.63

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$6M	+57.7%	$-0.75	$-0.85–$-0.67	—	7
2027	$18M	+210.5%	$-0.70	$-1.00–$-0.35	—	7
2028	$41M	+129.5%	$-0.44	$-0.83–$0.26	—	6
2029	$42M	+3.7%	$-0.37	$-1.43–$0.05	—	3

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 3 of the last 8 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-08-11	$-0.19	$-0.18	+5.8%
2026-05-07	$-0.20	$-0.19	+5.0%
2026-03-24	$-0.16	$-0.23	-43.8%
2025-11-12	$-0.19	$-0.20	-5.3%
2025-08-12	$-0.19	$-0.24	-26.3%
2025-05-13	$-0.23	$-0.21	+8.7%
2025-03-18	$-0.22	$-0.25	-13.6%
2024-11-12	$-0.19

DCF fair valuemodel estimate

Intrinsic value

$0.04

Price

$9.46

Implied downside

-100%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
ABSIAbsci Corporation	$9.46	-0.42%	$1.6B	—
CRVSCorvus Pharmaceuticals, Inc.	$15.14	+0.60%	$1.3B	—
ERASErasca, Inc.	$17.86	-3.88%	$6.2B	—
GOSSGossamer Bio, Inc.	$0.17	-4.11%	$83M	—
MGTXMeiraGTx Holdings plc	$12.67	-2.24%

Absci Corporation Common Stock

Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process. Its lead product candidate, ABS-201, is an anti-prolactin receptor (PRLR) antibody engineered with an extended half-life to support a patient-friendly dosing interval.

www.absci.com

Employees: 140
IPO / List date: Jul 22, 2021
HQ: VANCOUVER, WA

Held by traders on TradeandTell

No one on the platform currently holds ABSI.

Super investors & insiders

Institutions holding (13F)

No tracked institution reports a position in ABSI as of their last filing.

Insider activity (SEC Form 4)

Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded ABSI yet.

$ABSI chatter on StockTwits

Moving Averages Cross@MAs_Crxss12h
$ABSI @PanicSeIler haven’t touched these lines in literally MONTHS.
View on StockTwits ↗
Moving Averages Cross@MAs_CrxssBullish1d
$ABSI this thing is invincible.
View on StockTwits ↗
Mike@7m3835d3Bullish1d
$ABSI told y’all we will finish green today! Exciting times ahead!
View on StockTwits ↗
JOHNWAYNE@WINNINGWEEZERBullish1d
$ABSI https://www.google.com/amp/s/simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-absi/absci/news/absci-absi-could-be-32-undervalued-following-abs-201-data-an/amp💪🏾🍷
View on StockTwits ↗
JOHNWAYNE@WINNINGWEEZERBullish1d
$ABSI https://www.marketbeat.com/instant-alerts/absci-nasdaqabsi-receives-buy-rating-from-needham-company-llc-2026-08-12/💪🏾🍷
View on StockTwits ↗
Duke Cramer@DUKEPROFITS1d
$ABSI ….BOO BOO BEARS!!!
View on StockTwits ↗
Open Outcrier@OpenOutcrier1d
$ABSI (-8.6% pre) Absci earnings missed by $0.02, revenue fell short of estimates https://ooc.bz/l/110966
View on StockTwits ↗
Fractal@JennyRowes1d
$ABCL for all those worried about share price post offering, I) this is a long game and a few points of dilution after a 200% rise this year is nothing, ii) company becomes fully loaded to develop 635 to approval, which is an awesome use of proceeds, and iii) financing maybwell attract interest and buying from big funds. $ABSI raised 100 M in Jube at ariund 7 bucks, then quickly traded up 11, in less than a month. I’m feeling very good about this one
View on StockTwits ↗
J@DoozioBullish2d
$ABSI vs last weeks lows?
View on StockTwits ↗
DonCorleone77@DonCorleone772d
$LITE $UAMY $ABSI $SVV AFTER-HOURS MOVERS: Currently Higher After Earnings: - Velo3D (VELO) up 19.3% - H&R Block (HRB) up 15.8% - CoreWeave (CRWV) up 15.7% - CAVA Group (CAVA) up 11.8% - Super Micro Computer (SMCI) up 7.6% - Lumentum (LITE) up 2.4% Currently Lower After Earnings: - United States Antimony (UAMY) down 15.2% - Absci (ABSI) down 10.0% Currently Also Lower: - Savers Value Village (SVV) down 8.8% after equity offering.
View on StockTwits ↗
don boonstra@teaman602d
$ABSI Enough money to last less than 2 years. They will need more funding in the next 12 months to move forward as a relevant company
View on StockTwits ↗
Mike@7m3835d3Bullish2d
$ABSI direct quote from the call: "As you saw in June, we announced that Eli Lilly made a $40 million strategic investment in Absci. Our partnership with Eli Lilly is tailored around the clinical development strategy for ABS-201. As a part of this collaboration, we are happy to be welcoming a representative from Lilly onto our Endometriosis Advisory Board. Zach will provide more details of this partnership later in the call. In addition to Lilly, we've seen elevated interest from the investment community in prolactin biology." If phase 2 endometriosis data in H2 2027 look good, I can imagine that Absci will partner with Lilly for endometriosis indication only. That way, Lilly will finance the phase 3 trial and do the heavy lifting in negotiations with insurance companies etc, while Absci can use the funds for pattern hair loss and the associated phase 3 and commercialization. Huge opportunity and great outlook!
View on StockTwits ↗
MarketBeat Earnings@EarningsInsider2d
https://www.marketbeat.com/earnings/reports/2026-8-11-absci-corp-stock/ $ABSI Absci Earnings Transcript
View on StockTwits ↗
AJ@RazorbackAJ2d
$ABSI Disaster of an earnings and shorting between $7.80 and $8.20; could see a huge haircut tomorrow. Current trailing stop at $8.80. Follow for setups like this — exact entries, precise stop levels, nothing vague. This is how I trade, not financial advice.
View on StockTwits ↗
Mike@7m3835d3Bullish2d
$ABSI alright, good conference call. Sounds all very bullish and super excited for the next few months! The reason it’s down is just the revenue, which doesn’t really matter. Balance sheet looks good with runway into H2 2028. Tomorrow will look very different and I wouldn’t be surprised if we will close green
View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.